newsfilter
← Latest News
GlobeNewswire·

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its